These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 16820980)

  • 1. The role of substance P in stress and anxiety responses.
    Ebner K; Singewald N
    Amino Acids; 2006 Oct; 31(3):251-72. PubMed ID: 16820980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry.
    Ebner K; Muigg P; Singewald G; Singewald N
    Ann N Y Acad Sci; 2008 Nov; 1144():61-73. PubMed ID: 19076365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of NK1 receptors in metabolic stress markers after the central administration of substance P.
    Mello DM; Marcinichen DR; Madruga D; Branco R; Paschoalini MA; De Lima TC
    Behav Brain Res; 2007 Aug; 181(2):232-8. PubMed ID: 17540463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurobiology of substance P and the NK1 receptor.
    Mantyh PW
    J Clin Psychiatry; 2002; 63 Suppl 11():6-10. PubMed ID: 12562137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats.
    Ebner K; Rupniak NM; Saria A; Singewald N
    Proc Natl Acad Sci U S A; 2004 Mar; 101(12):4280-5. PubMed ID: 15024126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
    Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders.
    Ressler KJ; Nemeroff CB
    Depress Anxiety; 2000; 12 Suppl 1():2-19. PubMed ID: 11098410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential therapeutic targets for neurokinin-1 receptor antagonists.
    Duffy RA
    Expert Opin Emerg Drugs; 2004 May; 9(1):9-21. PubMed ID: 15155133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1).
    Santarelli L; Gobbi G; Blier P; Hen R
    J Clin Psychiatry; 2002; 63 Suppl 11():11-7. PubMed ID: 12562138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiolytic-like effects of substance P administration into the dorsal, but not ventral, hippocampus and its influence on serotonin.
    Carvalho MC; Masson S; Brandão ML; de Souza Silva MA
    Peptides; 2008 Jul; 29(7):1191-200. PubMed ID: 18490080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between NPY and CRF in the amygdala to regulate emotionality.
    Sajdyk TJ; Shekhar A; Gehlert DR
    Neuropeptides; 2004 Aug; 38(4):225-34. PubMed ID: 15337374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurokinin-1 receptor deletion modulates behavioural and neurochemical alterations in an animal model of depression.
    Roche M; Kerr DM; Hunt SP; Kelly JP
    Behav Brain Res; 2012 Mar; 228(1):91-8. PubMed ID: 22155476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
    Herpfer I; Lieb K
    CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the anxiolytic-like effect of TRH and the response of amygdalar TRHergic neurons in anxiety.
    Gutiérrez-Mariscal M; de Gortari P; López-Rubalcava C; Martínez A; Joseph-Bravo P
    Psychoneuroendocrinology; 2008 Feb; 33(2):198-213. PubMed ID: 18079066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substance P neurokinin 1 receptor activation within the dorsal raphe nucleus controls serotonin release in the mouse frontal cortex.
    Guiard BP; Guilloux JP; Reperant C; Hunt SP; Toth M; Gardier AM
    Mol Pharmacol; 2007 Dec; 72(6):1411-8. PubMed ID: 17890358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early life influences on life-long patterns of behavior and health.
    McEwen BS
    Ment Retard Dev Disabil Res Rev; 2003; 9(3):149-54. PubMed ID: 12953293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance P: A neuropeptide involved in the psychopathology of anxiety disorders.
    Iftikhar K; Siddiq A; Baig SG; Zehra S
    Neuropeptides; 2020 Feb; 79():101993. PubMed ID: 31735376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Peptides and anxiety].
    Dantzer R
    Encephale; 1983; 9(4 Suppl 2):177B-182B. PubMed ID: 6144513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of anxiety in rats evaluated in the elevated T-maze: evidence of the relationship between substance P and diazepam.
    Duzzioni M; Calixto AV; Duarte FS; De Lima TC
    Behav Brain Res; 2008 Feb; 187(1):140-5. PubMed ID: 17963853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NPY system in stress, anxiety and depression.
    Heilig M
    Neuropeptides; 2004 Aug; 38(4):213-24. PubMed ID: 15337373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.